Baloxavir marboxil in Chinese children aged 1 to under 5 years with influenza

Phase 4, open-label, single-arm trial of baloxavir marboxil in influenza, Influenza A infection and influenza B, sponsored by Beijing Children's Hospital. Primary endpoints: Change from baseline in vital sign measurements and Incidence, severity, and timing of adverse events. Started Mar 2025; status: completed.